David B Hanna1, Nancy A Hessol, Elizabeth T Golub, Jennifer M Cocohoba, Mardge H Cohen, Alexandra M Levine, Tracey E Wilson, Mary Young, Kathryn Anastos, Robert C Kaplan. 1. *Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY; †Department of Clinical Pharmacy, University of California-San Francisco, San Francisco, CA; ‡Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; §Department of Medicine, Cook County Health and Hospitals System and Rush University, Chicago, IL; ‖City of Hope National Medical Center, Duarte, CA; ¶Department of Community Health Sciences, SUNY Downstate Medical Center, Brooklyn, NY; #Department of Medicine, Georgetown University Medical Center, Washington, DC; and **Department of Medicine, Montefiore Medical Center, Bronx, NY.
Abstract
INTRODUCTION: The use of single-tablet antiretroviral therapy (ART) regimens and its implications on adherence among HIV-infected women have not been well described. METHODS: Participants were enrolled in the Women's Interagency HIV Study, a longitudinal study of HIV infection in US women. We examined semiannual trends in single-tablet regimen use and ART adherence, defined as self-reported 95% adherence in the past 6 months, during 2006-2013. In a nested cohort study, we assessed the comparative effectiveness of a single-tablet versus a multiple-tablet regimen with respect to adherence, virologic suppression, quality of life, and AIDS-defining events, using propensity score matching to account for demographic, behavioral, and clinical confounders. We also examined these outcomes in a subset of women switching from a multiple- to single-tablet regimen using a case-crossover design. RESULTS: We included 15,523 person-visits, representing 1727 women (53% black, 29% Hispanic, 25% IDU, median age 47). Use of single-tablet regimens among ART users increased from 7% in 2006% to 27% in 2013; adherence increased from 78% to 85% during the same period (both P < 0.001). Single-tablet regimen use was significantly associated with increased adherence (adjusted risk ratio: 1.05; 95% confidence interval: 1.03 to 1.08) and virologic suppression (risk ratio: 1.06; 95% confidence interval: 1.01 to 1.11), while associations with improved quality of life and fewer AIDS-defining events did not achieve statistical significance. Similar findings were observed among the subset of switchers. CONCLUSIONS: Single-tablet regimen use was associated with increased adherence and virologic suppression. Despite this, 15% of women prescribed ART were still not optimally adherent; additional interventions are needed to maximize therapeutic benefits.
INTRODUCTION: The use of single-tablet antiretroviral therapy (ART) regimens and its implications on adherence among HIV-infectedwomen have not been well described. METHODS:Participants were enrolled in the Women's Interagency HIV Study, a longitudinal study of HIV infection in US women. We examined semiannual trends in single-tablet regimen use and ART adherence, defined as self-reported 95% adherence in the past 6 months, during 2006-2013. In a nested cohort study, we assessed the comparative effectiveness of a single-tablet versus a multiple-tablet regimen with respect to adherence, virologic suppression, quality of life, and AIDS-defining events, using propensity score matching to account for demographic, behavioral, and clinical confounders. We also examined these outcomes in a subset of women switching from a multiple- to single-tablet regimen using a case-crossover design. RESULTS: We included 15,523 person-visits, representing 1727 women (53% black, 29% Hispanic, 25% IDU, median age 47). Use of single-tablet regimens among ART users increased from 7% in 2006% to 27% in 2013; adherence increased from 78% to 85% during the same period (both P < 0.001). Single-tablet regimen use was significantly associated with increased adherence (adjusted risk ratio: 1.05; 95% confidence interval: 1.03 to 1.08) and virologic suppression (risk ratio: 1.06; 95% confidence interval: 1.01 to 1.11), while associations with improved quality of life and fewer AIDS-defining events did not achieve statistical significance. Similar findings were observed among the subset of switchers. CONCLUSIONS: Single-tablet regimen use was associated with increased adherence and virologic suppression. Despite this, 15% of women prescribed ART were still not optimally adherent; additional interventions are needed to maximize therapeutic benefits.
Authors: Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg Journal: Curr HIV/AIDS Rep Date: 2011-12 Impact factor: 5.071
Authors: Michael J Mugavero; Andrew O Westfall; Anne Zinski; Jessica Davila; Mari-Lynn Drainoni; Lytt I Gardner; Jeanne C Keruly; Faye Malitz; Gary Marks; Lisa Metsch; Tracey E Wilson; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Linda Beer; James Heffelfinger; Emma Frazier; Christine Mattson; Brad Roter; Elizabeth Barash; Susan Buskin; Todd Rime; Eduardo Valverde Journal: Open AIDS J Date: 2012-09-07
Authors: Nancy A Hessol; Susan Holman; Howard Minkoff; Mardge H Cohen; Elizabeth T Golub; Seble Kassaye; Roksana Karim; Oluwakemi Sosanya; Christopher Shaheen; Zaher Merhi Journal: AIDS Care Date: 2015-08-14
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Morgan M Philbin; Carrigan Parish; Margaret Pereyra; Daniel J Feaster; Mardge Cohen; Gina Wingood; Deborah Konkle-Parker; Adebola Adedimeji; Tracey E Wilson; Jennifer Cohen; Lakshmi Goparaju; Adaora A Adimora; Elizabeth T Golub; Lisa R Metsch Journal: J Health Commun Date: 2019-06-14
Authors: Michael G Eberhart; Baligh R Yehia; Amy Hillier; Chelsea D Voytek; Danielle J Fiore; Michael Blank; Ian Frank; David S Metzger; Kathleen A Brady Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: David B Hanna; Uriel R Felsen; Mindy S Ginsberg; Barry S Zingman; Robert S Beil; Donna C Futterman; Howard D Strickler; Kathryn Anastos Journal: AIDS Res Hum Retroviruses Date: 2016-03-17 Impact factor: 2.205
Authors: Shilpa Viswanathan; Amy C Justice; G Caleb Alexander; Todd T Brown; Neel R Gandhi; Ian R McNicholl; David Rimland; Maria C Rodriguez-Barradas; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub Journal: AIDS Behav Date: 2018-03
Authors: Claudia Reinheimer; Anna Wesner; Oliver T Keppler; Hans Wilhelm Doerr; Eva Herrmann; Martin Stürmer; Christoph Stephan Journal: Med Microbiol Immunol Date: 2016-01-08 Impact factor: 3.402